Cooper Companies vs West Pharmaceutical Services
Add, change or remove companies; up to four.
The short version
- Cooper Companies is the larger business, with $4.1B of revenue in fiscal 2025 against $3.1B for West Pharmaceutical Services.
- West Pharmaceutical Services grew revenue faster (6.3%, against 5.1%).
- West Pharmaceutical Services kept more of each dollar of sales as operating profit (19.0% operating margin, against 16.7%).
- West Pharmaceutical Services turned more of its sales into free cash flow (15.3% FCF margin, against 10.6%).
- West Pharmaceutical Services earned a higher return on the capital invested in it (18.7%, against 4.3%).
- Investors pay more for each dollar of West Pharmaceutical Services’s earnings: a P/E of 50.2x against 21.0x for Cooper Companies.
| Latest fiscal year | COO · FY25 | WST · FY25 |
|---|---|---|
| Size | ||
| Market cap | $11.8B | $28.0B |
| Revenue | $4.1B | $3.1B |
| Free cash flow | $434M | $469M |
| Net income | $375M | $494M |
| Growth | ||
| Revenue growth | 5.1% | 6.3% |
| 5-year growth | 11.0% | 7.4% |
| Share count change | −0.2% | −1.4% |
| Profitability | ||
| Gross margin | 65.5% | 35.9% |
| Operating margin | 16.7% | 19.0% |
| Net margin | 9.2% | 16.1% |
| FCF margin | 10.6% | 15.3% |
| Return on capital | 4.3% | 18.7% |
| Return on equity | 4.6% | 16.9% |
| Balance sheet | ||
| Net debt | $2.4B | −$583M |
| Net debt / EBITDA | 2.3x | −0.8x |
| Dividends and buybacks | $290M | $195M |
| Valuation & quality | ||
| P/E | 21.0x | 50.2x |
| Piotroski F-score | 5 | 9 |
Revenue
FY16
COO $2.0B
WST $1.5B
FY17
COO $2.1B
WST $1.6B
FY18
COO $2.5B
WST $1.7B
FY19
COO $2.7B
WST $1.8B
FY20
COO $2.4B
WST $2.1B
FY21
COO $2.9B
WST $2.8B
FY22
COO $3.3B
WST $2.9B
FY23
COO $3.6B
WST $2.9B
FY24
COO $3.9B
WST $2.9B
FY25
COO $4.1B
WST $3.1B
COO
WST
Operating margin
FY16
COO 16.5%
WST 12.9%
FY17
COO 20.1%
WST 14.1%
FY18
COO 15.9%
WST 14.0%
FY19
COO 20.6%
WST 16.1%
FY20
COO 12.8%
WST 19.0%
FY21
COO 17.3%
WST 26.6%
FY22
COO 15.3%
WST 25.4%
FY23
COO 14.8%
WST 22.9%
FY24
COO 18.1%
WST 19.7%
FY25
COO 16.7%
WST 19.0%
COO
WST
Free cash flow
FY16
COO $357M
WST $49.2M
FY17
COO $466M
WST $133M
FY18
COO $475M
WST $184M
FY19
COO $421M
WST $241M
FY20
COO $176M
WST $298M
FY21
COO $524M
WST $331M
FY22
COO $450M
WST $439M
FY23
COO $215M
WST $415M
FY24
COO $288M
WST $276M
FY25
COO $434M
WST $469M
COO
WST
Return on capital
FY16
COO 7.4%
WST 12.7%
FY17
COO 9.7%
WST 12.1%
FY18
COO 4.2%
WST 15.9%
FY19
COO 10.6%
WST 17.9%
FY20
COO 5.6%
WST 23.1%
FY21
COO 7.6%
WST 38.8%
FY22
COO 4.6%
WST 31.9%
FY23
COO 3.8%
WST 26.3%
FY24
COO 4.6%
WST 20.1%
FY25
COO 4.3%
WST 18.7%
COO
WST
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.